In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity.

Alzheimer's disease is a complex neurodegenerative disorder of the central nervous system, characterized by amyloid-β deposits, τ-protein aggregation, oxidative stress and reduced levels of acetylcholine in the brain. One pharmacological approach is to restore acetylcholine level by inhibiting acetylcholinesterase (AChE) with reversible inhibitors, such as galanthamine, thus helping to improve the cognitive symptoms of the disease. In order to design new galanthamine derivatives and search for novel, potential inhibitors with improved interactions, as well as a suitable pharmacokinetic profile and low toxicity, several molecular modeling techniques were applied. These techniques included the investigation of AChE-drug complexes (1QT1 and 1ACJ Protein Data Bank codes), ligand-binding sites calculation within the active site of the enzyme, pharmacophore perception of galanthamine derivatives, virtual screening, toxicophorical analysis and estimation of pharmacokinetics properties. A total of four galanthamine derivatives having a N-alkyl-phenyl chain were designed, since the tertiary amine substituents could reach the peripheral anionic site that is not occupied by galanthamine. In addition, 12 drug-like compounds from the Ilibdiverse database were selected by virtual screening as novel, hypothetical AChE inhibitors. The toxicophorical analysis revealed that only four proposed inhibitors have chemical groups able to develop mutagenicity and chromosome damage. The remaining compounds showed only mild or none toxicophorical alerts. At least three screened compounds presented theoric parameters consistent with good oral bioavailability. The designed molecules have the potential to become new lead compounds that might guide the design of drugs with optimized pharmacodynamic and pharmacokinetic properties in order to improve the treatment of Alzheimer's disease by creating new pharmacotherapeutic options.

[1]  J. Miller,et al.  CARCINOGENESIS AND INHIBITION OF THE WALKER 256 TUMOR IN THE RAT BY TRANS-4-ACETYLAMINOSTILBENE, ITS N-HYDROXY METABOLITE, AND RELATED COMPOUNDS. , 1964, Cancer research.

[2]  J. Seiler.  The mutagenicity of benzimidazole and benzimidazole derivatives. II. Incorporation of benzimidazole into the nucleic acids of Escherichia coli. , 1973, Mutation research.

[3]  H. Glatt,et al.  Rat hepatocyte-mediated bacterial mutagenicity in relation to the carcinogenic potency of benz(a)anthracene, benzo(a)pyrene, and twenty-five methylated derivatives. , 1987, Cancer research.

[4]  D A Basketter,et al.  Possible origin of the skin sensitization potential of isoeugenol and related compounds , 1992, Contact dermatitis.

[5]  J. Sussman,et al.  Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  F. Gage,et al.  Cholinergic strategies for Alzheimer’s disease , 1998, Journal of Molecular Medicine.

[7]  C. Guillou,et al.  Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. , 1998, Bioorganic & medicinal chemistry.

[8]  D A Basketter,et al.  Classification criteria for skin‐sensitizing chemicals: a commentary , 1999, Contact dermatitis.

[9]  A. Maelicke,et al.  Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer’s disease , 2000, Behavioural Brain Research.

[10]  K. Goa,et al.  Galantamine , 2000, Drugs.

[11]  D Lamba,et al.  Three‐dimensional structure of a complex of galanthamine (Nivalin®) with acetylcholinesterase from Torpedo californica: Implications for the design of new anti‐Alzheimer drugs , 2001, Proteins.

[12]  M. Wolfe.  Therapeutic strategies for Alzheimer's disease , 2002, Nature Reviews Drug Discovery.

[13]  M. Citron.  β‐secretase as a target for the treatment of Alzheimer's disease , 2002 .

[14]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[15]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[16]  Anabella Villalobos,et al.  Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. , 2004, European journal of pharmacology.

[17]  R. Martins,et al.  Age at onset: important marker of genetic heterogeneity in Alzheimer's disease , 2004, The Pharmacogenomics Journal.

[18]  Thierry Langer,et al.  Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. , 2004, Journal of medicinal chemistry.

[19]  J. Seiler.  The molecular mechanism of benzimidazole mutagenicity: In vitro studies on transcription and translation , 1975, Biochemical Genetics.

[20]  M. Rissel,et al.  Toxic Effects of Tacrine on Primary Hepatocytes and Liver Epithelial Cells in Culture , 1998, Cell Biology and Toxicology.

[21]  Richard M. Jackson,et al.  Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites , 2005, Bioinform..

[22]  C. Caltagirone,et al.  Guidelines for the Treatment of Alzheimer’s Disease from the Italian Association of Psychogeriatrics , 2005, Drugs & aging.

[23]  J. Marco-Contelles,et al.  Synthesis and pharmacology of galantamine. , 2006, Chemical reviews.

[24]  V. Papadopoulos,et al.  3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA. , 2006, Bioorganic & medicinal chemistry letters.

[25]  M. Goedert,et al.  A Century of Alzheimer's Disease , 2006, Science.

[26]  J. Growdon,et al.  Current pharmacotherapy for Alzheimer's disease. , 2006, Annual review of medicine.

[27]  A. Maelicke,et al.  The N-butylcarbamate derivative of galantamine acts as an allosteric potentiating ligand on alpha7 nicotinic receptors in hippocampal neurons: clinical implications for treatment of Alzheimer's disease. , 2006, Journal of molecular neuroscience : MN.

[28]  Peter Willett,et al.  GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D , 2006, J. Comput. Aided Mol. Des..

[29]  T. Svensson,et al.  Galantamine Enhances Dopaminergic Neurotransmission In Vivo Via Allosteric Potentiation of Nicotinic Acetylcholine Receptors , 2007, Neuropsychopharmacology.

[30]  Ivone Carvalho,et al.  Virtual Screening, Molecular Interaction Field, Molecular Dynamics, Docking, Density Functional, and ADMET Properties of Novel AChE Inhibitors in Alzheimer's Disease , 2007, Journal of biomolecular structure & dynamics.

[31]  T. Nabeshima,et al.  The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Ameliorates the Cognitive Dysfunction in Beta Amyloid25–35 I.c.v.-Injected Mice: Involvement of Dopaminergic Systems , 2007, Neuropsychopharmacology.

[32]  F. J. Luque,et al.  New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties. , 2008, Bioorganic & medicinal chemistry.

[33]  D. Holtzman.  Alzheimer's disease: Moving towards a vaccine , 2008, Nature.

[34]  Anshuman Dixit,et al.  An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis. , 2008, Journal of molecular graphics & modelling.